$5.1B deal: GSK to buy Boston-area cancer drug developer
Monday, 3 December 2018 In a major move to boost its oncology product pipeline, GlaxoSmithKline entered into a definitive agreement Monday to acquire Boston-area biopharmaceutical company Tesaro for $5.1 billion. Tesaro (NASDAQ: TSRO) of Waltham, Mass., markets the ovarian cancer therapy Zejula, which is approved in the United States and Europe. The company is also conducting clinical trials that if successful could lead to an expanded use of the drug, as a monotherapy and in combination with other ovarian cancer treatments. Hal…
It's a kinder, far gentler approach to killing cancer. A Long Beach oncologist is reporting a near miracle. A young woman with stage 4 cancer got better after taking an inexpensive drug used by millions of Americans. Sharon Tay reports.
A new study reveals a common prostate cancer drug has been linked to type 2 diabetes. According to UPI, researchers from the University of Edinburgh found that men taking 5-alpha-reductase inhibitors..